Repaglinide

Also Known As: Repaglinide, Prandin, GlucoNorm, Surepost, Repaglid

Repaglinide (Prandin in the U.S., GlucoNorm in Canada, Surepost in Japan,Repaglid in Egypt, NovoNorm elsewhere) is for the treatment of type II diabetes. It is supplied by Novo Nordisk. It is sold in Japan by Dainippon Sumitomo Pharma.

Repaglinide belongs to the meglitinide class of blood glucose-lowering drugs.

Repaglinide lowers blood glucose by stimulating the release of insulin from the pancreas. It achieves this by closing ATP-dependent potassium channels in the membrane of the beta cells. This depolarizes the beta cells, opening the cells' calcium channels, and the resulting calcium influx induces insulin secretion.

All Treatments

Average Effectiveness

This is the Average effectiveness per ailment as reported by our participants (you).

Effectiveness:

0 = No improvement or Worse
1 = Slight improvement
2 = Moderate Improvement
3 = Significant Improvement
4 = Cured

Order By

Type of Treatment

Date Range

Minimum Number of Users

Embed

Complete a survey on Repaglinide to help the CureCrowd community

If you have tried to treat this ailment, please complete the following form to help us better our data, and help guide people to the best possible treatments. CureCrowd is a public resource with absolutely no vested interest in the outcomes of our studies.